专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08512716B2 Diagnostic, predictive and prognostic testing for cancer 有权
标题翻译：癌症的诊断，预测和预后测试
公开(公告)号：US08512716B2
公开(公告)日：2013-08-20
申请号：US12738062
申请日：2008-10-15
申请人： Kai Stoeber , Gareth Hayden Williams
发明人： Kai Stoeber , Gareth Hayden Williams
IPC分类号： A61K38/00 , A61K35/12
CPC分类号： C12Q1/6886 , G01N33/574 , G01N33/57484 , G01N2800/56
摘要： The present invention relates to a method for determining a prognosis of progression of a cancer in a subject, a method for determining a treatment protocol for a subject having cancer or a method for determining efficacy of a therapeutic treatment of a subject, the method comprising the steps of: (a) assessing a level of a first biomarker selected from at least one of Mcm2-7 in a biological sample from the subject: and (b) assessing the level of a second biomarker selected from at least one of geminin, Aurora A, Plk1, Ki67 and H3S10ph in the biological sample from the subject, wherein the combination of the level of the first biomarker compared to a pre-determined value and the level of the second biomarker compared to a predetermined value is indicative of cancer progression in the subject or is indicative of the treatment regimen prescribed for the subject or is indicative of the efficacy of the therapeutic treatment.
摘要翻译：本发明涉及一种用于确定受试者中癌症进展的预后的方法，用于确定具有癌症的受试者的治疗方案的方法或用于确定受试者的治疗性治疗功效的方法，所述方法包括步骤：（a）评估选自所述受试者的生物样品中Mcm2-7中的至少一个的第一生物标志物的水平;和（b）评估选自下列至少一种的第二生物标志物的水平：麒麟，极光 A，Plk1，Ki67和H3S10ph，其中与预定值相比较的第一生物标记物的水平与第二生物标志物的水平与预定值相比的组合指示癌症进展该受试者或指示针对受试者规定的治疗方案或指示治疗性治疗的功效。

2. 发明申请

US20120077863A1 GUANIDINO-SUBSTITUTED BI-AND POLYPHENYLS AS SMALL MOLECULE CARRIERS 审中-公开
标题翻译：作为小分子载体的甘氨酸取代的双 - 聚双环
公开(公告)号：US20120077863A1
公开(公告)日：2012-03-29
申请号：US13203667
申请日：2010-03-01
申请人： David Selwood , Roberta Worthington , Anne-Sophie Rebstock , Michela Simone , Matt Gooding , Henry Dube , Kai Stoeber , Slavica Tudzarova , Christoffer Boshoff , Gareth Williams , Sarah Kingsbury , Dimitrios Lagos , Juan Manuel Funes Quesada
发明人： David Selwood , Roberta Worthington , Anne-Sophie Rebstock , Michela Simone , Matt Gooding , Henry Dube , Kai Stoeber , Slavica Tudzarova , Christoffer Boshoff , Gareth Williams , Sarah Kingsbury , Dimitrios Lagos , Juan Manuel Funes Quesada
IPC分类号： A61K31/713 , C12N5/071 , A61K31/155 , C07C279/08 , C07H21/02
CPC分类号： C07D277/18 , C07C279/08 , C07C279/24 , C07C323/60 , Y02P20/55
摘要： A compound of formula I, or a pharmaceutically acceptable salt thereof, wherein —X1, X2 and X3 are each independently where Y is an alkylene, alkenylene or alkynylene group, each of which may be optionally substituted with one or more substituents selected from alkyl, halo, CF3, OH, alkoxy, NH2, CN, NO2 and COOH; W is absent or is O, S or NH; R1, R2, R3 and R4 are each independently selected from H, alkyl, aryl and a protecting group Pi; R7, R8 and R9 are each independently selected from H, alkyl, halo, CF3, OH, alkoxy, CN, NO2 and COOH; —q is 1, 2, 3 or 4; q′ is 0, 1, 2 or 3, where q+q′ equals 4; p and r are each independently 1, 2, 3, 4 or 5; p′ and r′ are each independently 0, 1, 2, 3 or 4, where p+p′ and r+r′ each equal 5; and —n is 0, 1, 2, 3, 4, 5 or 6.
摘要翻译：式I化合物或其药学上可接受的盐，其中-X1，X2和X3各自独立地为Y为亚烷基，亚烯基或亚炔基，其各自可以任选地被一个或多个选自烷基，卤素，CF 3，OH，烷氧基，NH 2，CN，NO 2和COOH; W不存在或是O，S或NH; R1，R2，R3和R4各自独立地选自H，烷基，芳基和保护基团Pi; R 7，R 8和R 9各自独立地选自H，烷基，卤素，CF 3，OH，烷氧基，CN，NO 2和COOH; -q为1,2,3或4; q'为0,1,2或3，其中q + q'等于4; p和r各自独立地为1,2,3,4或5; p'和r'各自独立地为0,1,2,3或4，其中p + p'和r + r'各自等于5; 和-n是0，1，2，3，4，5或6。

3. 发明申请

US20100285474A1 DIAGNOSTIC, PREDICTIVE AND PROGNOSTIC TESTING FOR CANCER 有权
标题翻译：癌症的诊断，预测和预防性检测
公开(公告)号：US20100285474A1
公开(公告)日：2010-11-11
申请号：US12738062
申请日：2008-10-15
申请人： Kai Stoeber , Gareth Hayden Williams
发明人： Kai Stoeber , Gareth Hayden Williams
IPC分类号： G01N33/574 , G01N33/573 , C12Q1/68
CPC分类号： C12Q1/6886 , G01N33/574 , G01N33/57484 , G01N2800/56
摘要： The present invention relates to a method for determining a prognosis of progression of a cancer in a subject, a method for determining a treatment protocol for a subject having cancer or a method for determining efficacy of a therapeutic treatment of a subject, the method comprising the steps of: (a) assessing a level of a first biomarker selected from at least one of Mcm2-7 in a biological sample from the subject: and (b) assessing the level of a second biomarker selected from at least one of geminin, Aurora A, Plk1, Ki67 and H3S10ph in the biological sample from the subject, wherein the combination of the level of the first biomarker compared to a pre-determined value and the level of the second biomarker compared to a predetermined value is indicative of cancer progression in the subject or is indicative of the treatment regimen prescribed for the subject or is indicative of the efficacy of the therapeutic treatment.
摘要翻译：本发明涉及一种用于确定受试者中癌症进展的预后的方法，用于确定具有癌症的受试者的治疗方案的方法或用于确定受试者的治疗性治疗功效的方法，所述方法包括步骤：（a）评估选自所述受试者的生物样品中Mcm2-7中的至少一个的第一生物标志物的水平;和（b）评估选自下列至少一种的第二生物标志物的水平：麒麟，极光 A，Plk1，Ki67和H3S10ph，其中与预定值相比较的第一生物标记物的水平与第二生物标志物的水平与预定值相比的组合指示癌症进展该受试者或指示针对受试者规定的治疗方案或指示治疗性治疗的功效。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式